RxDoctor Payments Data

Saima Khan, MD

Internal Medicine · Warren, MINPI 1629157326

Payments from drug & device makers

$577in general payments, 2019–2025

Across 23 payments — averaging $25.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$174
  • Abiomed$149
  • Sanofi-aventis U.S. LLC$85
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$47
  • Pfizer$28
  • AbbVie$27
  • plus $67 from 3 others

What the payments were for

  • Food & beverage$577100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$577 in reported general payments places this provider in the 65th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$84,625
Medicare patients
146
Services billed
906

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate33$43,028
OzempicSemaglutide38$34,270
EliquisApixaban30$28,766
JardianceEmpagliflozin18$25,886
TrulicityDulaglutide16$16,384
Tiotropium Bromide12$11,762
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,922
Atorvastatin Calcium224$3,032
Albuterol Sulfate HfaAlbuterol Sulfate77$2,856
SynthroidLevothyroxine Sodium18$2,313
Omeprazole131$2,078
Ventolin HfaAlbuterol Sulfate22$1,997
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl13$1,782
Losartan Potassium129$1,708
Simvastatin142$1,585

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28$28,76630 claims
AbbVieSynthroid$27$2,31318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Warren

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →